Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A
This 12-month follow-up study from northeastern India confirms the sustained efficacy and safety of emicizumab in reducing bleeds and improving outcomes in children with HA. The findings underscore its value in underserved settings, supporting broader implementation in similar healthcare environments.
Authors
- A. K. Dutta
- Taniya Sarkar Dutta (ORCID: https://orcid.org/0000-0002-1739-2034)
- Yash Duseja
- Luish Borboruah (ORCID: https://orcid.org/0009-0006-8266-6691)
- Papori Gogoi
- Juhi Borah
Institutions
- Assam Medical College (IN)
Publication Details
- Journal
- Therapeutic Advances in Hematology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/20406207261419325
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00